References
- Stansfeld PJ, Gedeck P, Gosling M, Cox B, Mitcheson JS, Sutclif MJ. Drug block of the hERG potassium channel: insight from modeling. Proteins. 2007;68(2):568–580.
- Jervell A, Lang-Nielson F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J. 1957;54:59–68.
- Zhou Z, Gong Q, January CT. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome: pharmacological and temperature effects. J Biol Chem. 1999;274:31123–31126.
- Anderson CL, Delisle BP, Anson BD, et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking deficient) mechanism. Circulation. 2006;113:365–373.
- Moha ou Maati H, Ducroq J, Rivet J, Faivre JF, Le Grande M, Bois P Curcumin blocks the recombinant human cardiac KCNQ1/KCNE1 channels (IKs) stably expressed in HEK 293 cells. Congress de Physiologie de Pharmacologie et de Therapeutique; April 9–11, 2008; Clermont-Ferrand, France. Fund Clin Pharmacol. 2008;22(Suppl 1):1–102.
- Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–1372.
- Okada T, Ogawa S, Sadanaga T, Mitamura H. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol. 1996;27:84–89.
- Maciel NR, Reis PG, Kato KC, et al. Reduced cardio-vascular alterations of tarter emetic administered in long-circulating liposomes in rats. Toxicol Lett. 2010;199(3):234–238.
- Zachariae U, Giordanetto F, Leach AG. Side chain flexibilities in the human ether-a-go-go related potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. J Med Chem. 2009;52(14):4266–4276.
- Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposomal-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 1987;31(12):1897–1900.